Kiniksa Pharmaceuticals Ltd - Asset Resilience Ratio
Kiniksa Pharmaceuticals Ltd (KNSA) has an Asset Resilience Ratio of 39.09% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Kiniksa Pharmaceuticals Ltd to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Kiniksa Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Kiniksa Pharmaceuticals Ltd assets under control.
Liquid Assets Composition Over Time
This chart breaks down Kiniksa Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read KNSA liabilities breakdown for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $350.25 Million | 39.09% |
| Total Liquid Assets | $350.25 Million | 39.09% |
Asset Resilience Insights
- Very High Liquidity: Kiniksa Pharmaceuticals Ltd maintains exceptional liquid asset reserves at 39.09% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Kiniksa Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio
Compare Kiniksa Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 9.65% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Annual Asset Resilience Ratio for Kiniksa Pharmaceuticals Ltd (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Kiniksa Pharmaceuticals Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 32.54% | $248.48 Million | $763.63 Million | +22.20pp |
| 2024-12-31 | 10.34% | $60.05 Million | $580.55 Million | -8.36pp |
| 2023-12-31 | 18.70% | $98.42 Million | $526.32 Million | +3.93pp |
| 2022-12-31 | 14.77% | $67.89 Million | $459.67 Million | -10.89pp |
| 2021-12-31 | 25.66% | $59.73 Million | $232.80 Million | -34.28pp |
| 2020-12-31 | 59.93% | $209.44 Million | $349.46 Million | -13.32pp |
| 2019-12-31 | 73.25% | $186.45 Million | $254.53 Million | +0.16pp |
| 2018-12-31 | 73.09% | $235.33 Million | $321.96 Million | +72.87pp |
| 2017-12-31 | 0.22% | $105.00K | $47.49 Million | +0.04pp |
| 2016-12-31 | 0.19% | $105.00K | $56.47 Million | -- |
About Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-3… Read more